Joseph Meserve - Concepedia

Author

Joseph Meserve

University of California San Diego ORCID

Also Known As

J Meserve, J. Meserve, Joseph D. Meserve, Joseph Meserve

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

University of California San Diego New York University Icahn School of Medicine at Mount Sinai Dartmouth–Hitchcock Medical Center Indiana University – Purdue University Indianapolis

About

Joseph Meserve is an author at University of California San Diego specializing in medicine, outcomes research, and gastroenterology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	77
2	Public Health	1	1	20
3	Allergy	1	1	30
4	Emergency Medicine	1	1	13
5	Epidemiology	1	1	20

Joseph Meserve

Publications

804

Citations

H-Index

Page 1

	Year	Citations
Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium Neeraj Narula, Farhad Peerani, Joseph Meserve, The American Journal of Gastroenterology	2018	171
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn’s Disease Parambir S. Dulai, Brigid S. Boland, Siddharth Singh, Gastroenterology	2018	140
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases Joseph Meserve, Satimai Aniwan, Jenna L. Koliani‐Pace, Clinical Gastroenterology and Hepatology	2018	81
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis Parambir S. Dulai, Siddharth Singh, Niels Vande Casteele, Clinical Gastroenterology and Hepatology	2020	76
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease Eugenia Shmidt, Gursimran Kochhar, Justin Hartke, Inflammatory Bowel Diseases	2018	74
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis David M. Faleck, Adam C. Winters, Shreya Chablaney, Clinical Gastroenterology and Hepatology	2019	67
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis Dana J. Lukin, David M. Faleck, Ronghui Xu, Clinical Gastroenterology and Hepatology	2020	58
Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases Joseph Meserve, Jiyu Luo, Wenhong Zhu, Gastroenterology InflammationMaternal ImmunizationAllergyAutoimmune DiseaseImmunodeficiencies	2021	30
Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease Maria Barsky, Joseph Meserve, Helen Le, Digestive Diseases and Sciences Functional Gastrointestinal DisorderGastroenterologyOutcomes ResearchColonoscopyUlcerative Colitis	2020	20
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes Jenna L. Koliani‐Pace, Siddharth Singh, Michelle Luo, Inflammatory Bowel Diseases	2019	15

Page 1